TY - JOUR
T1 - Epcoritamab in relapsed/refractory large B-cell lymphoma
T2 - 2-year follow-up from the pivotal EPCORE NHL-1 trial
AU - Thieblemont, Catherine
AU - Karimi, Yasmin H.
AU - Ghesquieres, Herve
AU - Cheah, Chan Y.
AU - Clausen, Michael Roost
AU - Cunningham, David
AU - Jurczak, Wojciech
AU - Do, Young Rok
AU - Gasiorowski, Robin
AU - Lewis, David John
AU - Kim, Tae Min
AU - van der Poel, Marjolein
AU - Poon, Michelle Limei
AU - Feldman, Tatyana
AU - Linton, Kim M.
AU - Sureda, Anna
AU - Hutchings, Martin
AU - Dinh, Minh H.
AU - Kilavuz, Nurgul
AU - Soong, David
AU - Mark, Thomas
AU - Sacchi, Mariana
AU - Phillips, Tycel
AU - Lugtenburg, Pieternella J.
N1 - Publisher Copyright:
© The Author(s) 2024.
PY - 2024/9/25
Y1 - 2024/9/25
N2 - Primary results (median follow-up, 10.7 months) from the pivotal EPCORE® NHL-1 study in relapsed or refractory (R/R) large B-cell lymphoma (LBCL) demonstrated deep, durable responses with epcoritamab, a CD3xCD20 bispecific antibody, when used as monotherapy. We report long-term efficacy and safety results in patients with LBCL (N = 157; 25.1-month median follow-up). As of April 21, 2023, overall response rate was 63.1% and complete response (CR) rate was 40.1%. Estimated 24-month progression-free survival (PFS) and overall survival (OS) rates were 27.8% and 44.6%, respectively. An estimated 64.2% of complete responders remained in CR at 24 months. Estimated 24-month PFS and OS rates among complete responders were 65.1% and 78.2%, respectively. Of 119 minimal residual disease (MRD)-evaluable patients, 45.4% had MRD negativity, which correlated with longer PFS and OS. CR rates were generally consistent across predefined subgroups: 36% prior chimeric antigen receptor (CAR) T-cell therapy, 32% primary refractory disease, and 37% International Prognostic Index ≥3. The most common treatment-emergent adverse events were cytokine release syndrome (51.0%), pyrexia (24.8%), fatigue (24.2%), and neutropenia (23.6%). These results underscore the long-term benefit of epcoritamab for treating R/R LBCL with deep responses across subgroups, including patients with hard-to-treat disease and expected poor prognosis (ClinicalTrials.gov Registration: NCT03625037).
AB - Primary results (median follow-up, 10.7 months) from the pivotal EPCORE® NHL-1 study in relapsed or refractory (R/R) large B-cell lymphoma (LBCL) demonstrated deep, durable responses with epcoritamab, a CD3xCD20 bispecific antibody, when used as monotherapy. We report long-term efficacy and safety results in patients with LBCL (N = 157; 25.1-month median follow-up). As of April 21, 2023, overall response rate was 63.1% and complete response (CR) rate was 40.1%. Estimated 24-month progression-free survival (PFS) and overall survival (OS) rates were 27.8% and 44.6%, respectively. An estimated 64.2% of complete responders remained in CR at 24 months. Estimated 24-month PFS and OS rates among complete responders were 65.1% and 78.2%, respectively. Of 119 minimal residual disease (MRD)-evaluable patients, 45.4% had MRD negativity, which correlated with longer PFS and OS. CR rates were generally consistent across predefined subgroups: 36% prior chimeric antigen receptor (CAR) T-cell therapy, 32% primary refractory disease, and 37% International Prognostic Index ≥3. The most common treatment-emergent adverse events were cytokine release syndrome (51.0%), pyrexia (24.8%), fatigue (24.2%), and neutropenia (23.6%). These results underscore the long-term benefit of epcoritamab for treating R/R LBCL with deep responses across subgroups, including patients with hard-to-treat disease and expected poor prognosis (ClinicalTrials.gov Registration: NCT03625037).
U2 - 10.1038/s41375-024-02410-8
DO - 10.1038/s41375-024-02410-8
M3 - Journal article
C2 - 39322711
AN - SCOPUS:85204799823
SN - 0887-6924
JO - Leukemia
JF - Leukemia
ER -